NexEos Bio is focused on bringing novel tools and therapies to market that address the unmet needs of patients suffering with eosinophil-related diseases including eosinophilic esophagitis (EoE). NexEos’ lead program is a novel, non-invasive imaging agent for the diagnosis, treatment monitoring, and management of eosinophilic esophagitis (EoE), which has the potential to help improve patients’ quality of life, more rapidly diagnose their disease and thus may help delay disease progression.
We are developing, in collaboration with scientists at The University of Utah, a novel way to identify inflammation that occurs in eosinophil-related disorders such as eosinophilic esophagitis (EoE). In addition, we are pursuing early-stage programs to develop therapeutics for the treatment of underlying inflammation in a number of eosinophil-related diseases.
NexEos’ lead program is a novel, non-invasive imaging agent for the diagnosis, treatment and management of EoE - which may delay disease progression.
CEO
CSO & co-founder
Research specialist
Research specialist
Research specialist
Stay connected to everything happening at Altitude Lab.
You can trust us with your email. We don't spam.